These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38645666)

  • 1. Deleting SUV39H1 in CAR-T cells epigenetically enhances the antitumor function.
    Wang Y; Zhao G; Wang S; Li N
    MedComm (2020); 2024 May; 5(5):e552. PubMed ID: 38645666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors.
    López-Cobo S; Fuentealba JR; Gueguen P; Bonté PE; Tsalkitzi K; Chacón I; Glauzy S; Bohineust A; Biquand A; Silva L; Gouveia Z; Goudot C; Perez F; Saitakis M; Amigorena S
    Cancer Discov; 2024 Jan; 14(1):120-141. PubMed ID: 37934001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
    Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
    Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
    Prinzing B; Zebley CC; Petersen CT; Fan Y; Anido AA; Yi Z; Nguyen P; Houke H; Bell M; Haydar D; Brown C; Boi SK; Alli S; Crawford JC; Riberdy JM; Park JJ; Zhou S; Velasquez MP; DeRenzo C; Lazzarotto CR; Tsai SQ; Vogel P; Pruett-Miller SM; Langfitt DM; Gottschalk S; Youngblood B; Krenciute G
    Sci Transl Med; 2021 Nov; 13(620):eabh0272. PubMed ID: 34788079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
    Jung IY; Narayan V; McDonald S; Rech AJ; Bartoszek R; Hong G; Davis MM; Xu J; Boesteanu AC; Barber-Rotenberg JS; Plesa G; Lacey SF; Jadlowsky JK; Siegel DL; Hammill DM; Cho-Park PF; Berger SL; Haas NB; Fraietta JA
    Sci Transl Med; 2022 Nov; 14(670):eabn7336. PubMed ID: 36350986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas.
    Niborski LL; Gueguen P; Ye M; Thiolat A; Ramos RN; Caudana P; Denizeau J; Colombeau L; Rodriguez R; Goudot C; Luccarini JM; Soudé A; Bournique B; Broqua P; Pace L; Baulande S; Sedlik C; Quivy JP; Almouzni G; Cohen JL; Zueva E; Waterfall JJ; Amigorena S; Piaggio E
    Nat Commun; 2022 Jun; 13(1):3739. PubMed ID: 35768432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXO1 is a master regulator of CAR T memory programming.
    Doan A; Mueller KP; Chen A; Rouin GT; Daniel B; Lattin J; Chen Y; Mozarsky B; Markovska M; Arias-Umana J; Hapke R; Jung I; Xu P; Klysz D; Bashti M; Quinn PJ; Sandor K; Zhang W; Hall J; Lareau C; Grupp SA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
    Res Sq; 2023 Nov; ():. PubMed ID: 37986944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic reprogramming of CAR T cells for in vivo functional persistence against solid tumors.
    Saitakis M
    Genes Immun; 2024 Feb; ():. PubMed ID: 38388813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Zheng W; Wei J; Zebley CC; Jones LL; Dhungana Y; Wang YD; Mavuluri J; Long L; Fan Y; Youngblood B; Chi H; Geiger TL
    Blood; 2021 Jul; 138(2):122-135. PubMed ID: 33690816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory-Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand.
    Ando M; Kondo T; Tomisato W; Ito M; Shichino S; Srirat T; Mise-Omata S; Nakagawara K; Yoshimura A
    Cancer Res Commun; 2021 Oct; 1(1):41-55. PubMed ID: 36860911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells.
    Zhu Z; Lou G; Teng XL; Wang H; Luo Y; Shi W; Yihunie K; Hao S; DeGolier K; Liao C; Huang H; Zhang Q; Fry T; Wang T; Yao C; Wu T
    Nat Immunol; 2024 Jan; 25(1):117-128. PubMed ID: 38012417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells.
    Zhang X; Zhang C; Qiao M; Cheng C; Tang N; Lu S; Sun W; Xu B; Cao Y; Wei X; Wang Y; Han W; Wang H
    Cancer Cell; 2022 Nov; 40(11):1407-1422.e7. PubMed ID: 36240777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
    Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
    Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
    Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schrödinger's T Cells: Molecular Insights Into Stemness and Exhaustion.
    Gonzalez NM; Zou D; Gu A; Chen W
    Front Immunol; 2021; 12():725618. PubMed ID: 34512656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NR4A transcription factors limit CAR T cell function in solid tumours.
    Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
    Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
    Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.